载药微球经动脉化疗栓塞治疗大肝癌的临床效果  

Clinical effect of drug-loaded microspheres transcatheter arterial chemoembolization treating large liver cancer

作　　者：周召海[1] 周建辉 刘洪军[1] ZHOU Zhao-hai;ZHOU Jian-hui;LIU Hong-jun(Department of Intervention,Pingdu People′s Hospital,Shandong Province,Pingdu266700,China)

机构地区：[1]山东省平度市人民医院介入科,山东平度266700

出　　处：《中国当代医药》2020年第22期87-90,共4页China Modern Medicine

摘　　要：目的探讨载药微球经动脉化疗栓塞治疗大肝癌的临床效果。方法选取2017年1月~2019年1月我院收治的行经动脉化疗栓塞的大肝癌患者73例资料进行回顾性分析,其中行载药微球肝动脉化疗栓塞术(DEB-TACE)35例(观察组),传统肝动脉化疗栓塞术(c-TACE)38例(对照组),在治疗前及治疗后第3、7天进行实验室检查,治疗前及治疗后1月行强化CT检查,对患者的影像资料及临床资料进行汇总分析,比较两种治疗方法在患者肿瘤反应、并发症及不良反应发生率的差异。结果治疗后第3天及第7天两组患者的丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)均高于本组治疗前,差异有统计学意义(P<0.05);治疗后第3天及第7天两组间ALT和AST比较,差异无统计学意义(P>0.05);两组均未发生严重的不良反应;治疗后1个月两组疾病缓解率与疾病控制率比较,差异无统计学意义(P>0.05)。结论 DEB-TACE治疗大肝癌安全有效,值得临床推广应用。Objective To investigate the clinical effect of drug-loaded microspheres transcatheter arterial chemoembolization(DEB-TACE)treating large liver cancer.Methods A retrospective analysis of 73 cases of large liver cancer patients undergoing transarterial arterial chemoembolization admitted to our hospital from January 2017 to January 2019,including 35 cases of drug-loaded microsphere hepatic arterial chemoembolization(DEB-TACE)(observation group),38 cases of traditional hepatic arterial chemoembolization(c-TACE)(control group),laboratory tests were performed before treatment and on days 3 and 7 after treatment,and intensive CT examination was performed before treatment and 1 month after treatment.The imaging data and clinical data were analyzed and summarized to compare the differences in the incidence of tumor response,complications and adverse reactions between the two treatment methods in patients.Results The alanine aminotransferase(ALT)and aspartate aminotransferase(AST)of patients of the two groups on the 3rd and 7th days after treatment were higher than those in this group before treatment,and the differences were statistically significant(P<0.05).There were no significant differences in ALT and AST between the two groups on the 3rd and 7th days after treatment(P>0.05).There were no serious adverse reactions in both groups;there were no significant differences in the disease remission rate and disease control rate at 1 month after treatment between two groups(P>0.05).Conclusion DEB-TACE is safe and effective in the treatment of large liver cancer,and it is worthy of clinical application.

关 键 词：肝癌 肝动脉 化学栓塞 载药微球 治疗效果 

分 类 号：R735.7[医药卫生—肿瘤]